Salix Pharmaceuticals (SLXP)
Salix Pharmaceuticals Revenue Growth: 61.60%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
SLXP Revenue Growth Rankings
| Overall | 93rd percentile | 262 of 4363 |
| Sector | 87th percentile | 59 of 457 in Healthcare |
| Industry | 63rd percentile | 4 of 11 in Drugs - Generic |
SLXP Revenue Growth Range, Past 5 Years
| Minimum | -42.70% | Mar 2008 |
| Maximum | 140.3% | Mar 2011 |
| Average | 30.60% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these SLXP related companies
SLXP News
Market Wrap Video + Additions to Watch List http://stks.co/442N including: $AH $LQDT $AMLN $PETM $SLXP
about 18 hours ago by StockTiger
about 18 hours ago by StockTiger
RT @StockTiger Market Wrap Video + Additions to Watch List http://stks.co/43sP including: $AH $LQDT $AMLN $PETM $SLXP
about 20 hours ago by sssc
about 20 hours ago by sssc
Market Wrap Video + Additions to Watch List http://stks.co/43h3 including: $AH $LQDT $AMLN $PETM $SLXP
about a day ago by StockTiger
about a day ago by StockTiger
Salix Pharmaceuticals to Present at Three Investment Conferences in June
May 29, 7:00AM Business Wire
May 29, 7:00AM Business Wire
Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2012
May 18, 7:00AM Business Wire
May 18, 7:00AM Business Wire
RT @TraderFlorida $LNKD http://stks.co/3r1e Hanging tough $MNST $SLXP too
about 17 days ago by stockeye
about 17 days ago by stockeye
@Fibline Nice list yessir, liking $SLXP from last week, bought $ARIA today, like the divy on $PDLI, hope it breaks up
about 18 days ago by harmongreg
about 18 days ago by harmongreg
RS Gainers (20in5) $FE $XL $SLXP $D $CTL $TECH $PTEN $STUDY http://chart.ly/fu38dfn
about 22 days ago by gtlackey
about 22 days ago by gtlackey
What Do Willow Trees Have to Do with Pharmaceuticals | via @harmongreg http://stks.co/3jt9 $SLXP
about 24 days ago by STNet
about 24 days ago by STNet
What Do Willow Trees Have to Do with Pharmaceuticals? http://stks.co/3jXP via @harmongreg $SLXP
about 24 days ago by StockTwits
about 24 days ago by StockTwits
What Do Willow Trees Have to Do with Pharmaceuticals http://stks.co/3jVI $SLXP
about 24 days ago by harmongreg
about 24 days ago by harmongreg
Listen to $SLXP at deutsche bank ag health care conference - live at 04:10 PM, ondemand after - http://stks.co/3jEt
about 24 days ago by earningscast
about 24 days ago by earningscast
Auriga Reiterates a 'Hold' on Salix Pharmaceuticals (SLXP); Q1 Tops Estimates, But Upside Priced In
May 08, 10:47AM Street Insider
May 08, 10:47AM Street Insider
UPDATE: Jefferies Raises PT to $63 on Salix Pharmaceuticals; Q1 Beat and Raised Guidance
May 08, 7:34AM Benzinga
May 08, 7:34AM Benzinga
$RAX looks like that earnings play worked. $SLXP have to wait till tomorrow to see.
about 25 days ago by MaddStocks
about 25 days ago by MaddStocks
$SLXP Good buy area here at the $50 level. Several indicators showing a long entry here as it tries to regain the 50DMA>
about 30 days ago by IndianTrader
about 30 days ago by IndianTrader
Salix Pharmaceuticals to Present at Three Investment Conferences in May
May 01, 7:00AM Business Wire
May 01, 7:00AM Business Wire
FDA Extends PDUFA Date for Priority Review of NDA for Salix Pharma's (SLXP) Crofelemer Tablets
Apr 30, 2:15PM Street Insider
Apr 30, 2:15PM Street Insider
Salix Pharmaceuticals Announces Extension of Crofelemer NDA Priority Review
Apr 30, 2:13PM Business Wire
Apr 30, 2:13PM Business Wire
Salix (SLXP), Progenics (PGNX) Get FDA PDUFA Extension Date for RELISTOR
Apr 25, 8:01AM Street Insider
Apr 25, 8:01AM Street Insider
Salix and Progenics Announce FDA Extension of RELISTOR® sNDA Goal Date to July 27, 2012
Apr 25, 8:00AM Business Wire
Apr 25, 8:00AM Business Wire
Salix Pharmaceuticals Announces 1Q2012 Financial Results Conference Call and Webcast
Apr 23, 7:00AM Business Wire
Apr 23, 7:00AM Business Wire
This tight channel after a significant sell off looks weak to me. Lower prices may be ahead. $SLXP http://chart.ly/j8vo9ed
about 46 days ago by TradetheLeaders
about 46 days ago by TradetheLeaders
Cantor Fitzgerald Maintains a 'Buy' on Salix Pharmaceuticals (SLXP); Suggests Buying Into Weakness
Apr 11, 8:22AM Street Insider
Apr 11, 8:22AM Street Insider
$SLXP lost 4% in heavy trade after brokerage Auriga downgraded the stock to hold from buy and lowered its price target to $51 from $54.
about 52 days ago by abubnic
about 52 days ago by abubnic
UPDATE - Auriga Downgrades Salix Pharma (SLXP) to Hold; Potential Limited on Relistor
Apr 10, 11:25AM Street Insider
Apr 10, 11:25AM Street Insider
Awsme RT @Sector_Trends: Weekly IBD group and sector rotation analysis posted http://stks.co/3G67 $QCOR $PRXL $WCG $CNC $SLXP $ACHN $VRX
about 55 days ago by purecharger
about 55 days ago by purecharger
Still holding 50DMA - not much to do until it either makes a new high or breaks the 50DMA $SLXP http://chart.ly/n7gxvgm
about 57 days ago by TradetheLeaders
about 57 days ago by TradetheLeaders
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SLXP | 51.43 | -0.38 | -0.73% | 3.079B |
| SLX | 40.95 | -1.00 | -2.38% | |
| SLW | 26.64 | +1.16 | +4.55% | 9.008B |
| VOXX | 9.56 | -0.30 | -3.04% | 205.19M |
| VOX | 62.61 | -1.55 | -2.42% | |
| VOOV | 55.76 | -1.81 | -3.14% | |
| VOG | 1.74 | -0.13 | -6.95% | 108.18M |
| VOD | 26.78 | -0.01 | -0.04% | 136.24B |
| VOCS | 15.72 | -0.41 | -2.54% | 327.12M |
| UTHR | 43.01 | -1.23 | -2.78% | 2.373B |